What is the primary purpose of this 10-Q filing?

The primary purpose of this 10-Q filing is to provide a quarterly update on Eli Lilly and Company's financial performance and condition to investors and regulatory bodies. It details financial statements, management discussion and analysis, and other relevant business information for the period ending June 29, 1998.

What key financial metrics should investors look for in a 10-Q report from this era?

Investors in a 1998 10-Q would typically focus on revenue growth, net income, earnings per share (EPS), gross margins, operating expenses (especially R&D and SG&A), and cash flow from operations. They would also examine balance sheet items like cash, debt levels, and inventory.

Given the industry, what non-financial aspects are crucial in this filing?

Beyond financial figures, investors would scrutinize the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' section for insights into drug pipeline progress (clinical trial status, new drug approvals), competitive landscape, regulatory challenges or approvals, and any strategic initiatives or risks facing the company.

Where can I find the actual financial statements and detailed analysis within the full 10-Q report?

The provided text is merely a directory listing of the filing's components on the SEC's EDGAR system. To access the financial statements, management discussion, and other detailed sections, you would need to locate and view the full report document (typically a .txt or HTML file) associated with this filing from the SEC's EDGAR database.

LLY 10-Q Quarterly Report Q2 FY1998 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company's 10-Q filing for the period ending June 29, 1998, provides a snapshot of the company's financial performance during the second quarter of that year. Investors should note the company's continued focus on its pharmaceutical pipeline and existing product lines. While specific financial figures like revenue and net income are not detailed in the provided text, the filing indicates ongoing operational activities and potential strategic developments that would have been of interest to shareholders at the time. The report emphasizes the dynamic nature of the pharmaceutical industry, with companies like Eli Lilly heavily invested in research and development to bring new therapies to market. Investors would have been looking for information regarding the progress of clinical trials, regulatory approvals, and the commercial performance of key drugs. The filing, therefore, serves as a key piece of information for understanding the company's trajectory and its ability to generate future growth and shareholder value in a competitive landscape.

Key Highlights

1The filing is a 10-Q report for Eli Lilly and Company (LLY) for the quarter ending June 29, 1998.
2The report was filed on August 12, 1998, offering a look at mid-1998 performance.
3This document is part of the SEC's EDGAR database, accessible to investors.
4The content provided is a directory listing of the filing, not the full financial statements.
5Investors would typically use such filings to assess financial health, operational performance, and strategic direction.
6The pharmaceutical industry, where Eli Lilly operates, is characterized by significant R&D investment and regulatory oversight.

ELI LILLY & Co Quarterly Report for Q2 Ended Jun 30, 1998

Summary

Key Highlights

Frequently Asked Questions